GlassScriptPhysician profile
Bradley Eric Cross
NPI 1932639572
$4,535.37
in general payments reported to CMS, 2019-2025
32 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.26 · 2020: $377 · 2021: $1,485 · 2022: $1,149 · 2023: $824 · 2024: $277 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $642.06 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $625.56 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Glaxosmithkline, LLC. | $618.92 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $434.18 | 2021-2025 | |
| Lilly USA, LLC | $216.23 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.95 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $186.56 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $181.58 | 2020-2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.35 | 2021-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $139.80 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $119.32 | 2022 | |
| Sumitomo Pharma America, INC. | $113.63 | 2023 | Gemtesa |
| Mylan Specialty L.P. | $112.25 | 2020-2022 | |
| Eisai INC. | $91.39 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $83.27 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $82.84 | 2021-2023 | Xarelto |
| Astellas Pharma US INC | $59.56 | 2023 | Myrbetriq, Veozah |
| Biogen, INC. | $57.17 | 2021 | |
| Allergan, INC. | $54.39 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $50.82 | 2025 | Ajovy, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $46.30 | 2022-2023 | Trintellix |
| Amgen INC. | $45.23 | 2022-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $29.63 | 2023-2025 | Cologuard Collection Kit |
| Alk-Abello, INC | $29.59 | 2022-2024 | Ragwitek, Odactra, Grastek |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.28 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $28.14 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.26 | 2025 | Rexulti |
| Beckman Coulter, INC. | $19.87 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.11 | 2022 | |
| Dexcom, INC. | $16.64 | 2023 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $16.41 | 2020 | |
| Antares Pharma, INC. | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.